Global HIV Vaccine Enterprise

What Global HIV Vaccine Enterprise does

The Global HIV Vaccine Enterprise, now operating as the HIV Vaccine Research Network, is a Geneva-based non-profit programme under the International AIDS Society (IAS) that strengthens African leadership in HIV vaccine research through training, mentorship, and advocacy. The organization was originally founded in 2003 as an independent entity and transitioned to an IAS programme in 2018, rebranding as the HIV Vaccine Research Network. It targets early- to mid-career African HIV vaccine researchers, advocates, policy makers, and community leaders, delivering capacity-building via three integrated modules: HIV Vaccine Science Academies (97 change makers since 2023), the HIV Vaccine Mentorship Programme (50 mentees since 2022), and Advocacy Initiatives (18 policy makers since 2022), supplemented by webinars, workshops, and conference-based networking at AIDS Conference, IAS Conference on HIV Science, and HIVR4P.

The network's underlying technology is minimal: its core delivery channels are the IAS+ interactive digital learning platform (e-learning courses, webinars, conference recordings) and multilingual content distribution across 10 languages. There are no proprietary technology products, no AI/ML components, and no commercial offerings. The programme operates as a non-revenue-generating capacity-building initiative, providing all services free of charge to qualifying participants. Distribution occurs through self-serve digital access via IAS+, direct programme engagement for academies and mentorship, and field-based outreach at major HIV conferences and regional meetings across Africa.

The business model is grant-funded philanthropy. The network's only disclosed revenue sources are institutional grants from the Bill & Melinda Gates Foundation and ANRS (Agence Nationale de Recherche sur le Sida et les hépatites virales), with no commercial pricing, contracts, or fee-for-service components. The go-to-market motion is community-led, leveraging IAS's established global HIV professional ecosystem, conference convening power, and multilingual digital infrastructure to reach researchers and advocates. With 1-10 employees and an integrated operating model embedded within IAS's broader portfolio, the network functions as a coordinated human-capital and knowledge-mobilisation initiative rather than a standalone commercial or technology entity.

Name

Global HIV Vaccine Enterprise

Legal name

International AIDS Society

Website

https://vaccineenterprise.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

The Global HIV Vaccine Enterprise operates as the HIV Vaccine Research Network, a Geneva-based non-profit programme under the International AIDS Society that builds capacity, mentorship, and advocacy among early- to mid-career African researchers, advocates, and policy makers to advance HIV vaccine research and leadership.

Ownership category

akta.pro rank

Product category

HIV Vaccine Research and Capacity Building

NAICS

Educational Support Services (61171), Educational Support Services (611710), Human Rights Organizations (813311)

SIC

Services-Social Services (8300), Services-Membership Organizations (8600), Services-Educational Services (8200)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Global Immunization & Vaccine Access Alliances (HLAJAKAK), HIV/AIDS Medicine (HLAKAGAB), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• HIV vaccine research
• Research capacity building
• Scientific mentorship programmes
• HIV advocacy training
• African research leadership

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant funding and philanthropic contributions: As an IAS programme, the network is funded through grants and contributions from institutional donors including The Bill & Melinda Gates Foundation and ANRS (Agence Nationale de Recherche sur le Sida). There is no commercial revenue model as the network operates as a non-profit capacity-building initiative.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The HIV Vaccine Research Network strengthens African leadership in HIV vaccine research by supporting early- to mid-career researchers and advocates through training, mentorship, and targeted capacity building. It delivers HIV Vaccine Science Academies, a structured mentorship programme with global experts, advocacy training for policy engagement, and knowledge-mobilising webinars and workshops, while elevating African voices through speaking and networking at major HIV conferences.

Product overview

The Global HIV Vaccine Enterprise (now the HIV Vaccine Research Network, an IAS programme since 2018) is a coordination and capacity-building initiative rather than a product company. It operates as a network programme that strengthens African leadership in HIV vaccine research. The core offering is the HIV Vaccine Research Network itself, supported by three integrated modules: the HIV Vaccine Science Academies (training), the HIV Vaccine Mentorship Programme (mentorship), and Advocacy Initiatives (policy engagement). Webinars and workshops provide ongoing knowledge mobilization. The IAS+ digital learning platform (a separate but affiliated IAS product) extends access to educational content, courses, and conference resources.

Differentiator

Problem solved

Functional benefit

Products and services

• HIV Vaccine Research Network The core network programme that strengthens African leadership in HIV vaccine research by supporting early- to mid-career researchers and advocates through training, mentorship, and capacity building, fostering collaboration between researchers, policy makers, advocates, and community leaders.
• HIV Vaccine Science Academies Intensive training programmes building research capacity through virtual learning and hands-on skills training for early- to mid-career African researchers and advocates working in HIV vaccine science.
• HIV Vaccine Mentorship Programme Structured mentorship programme pairing emerging African researchers with global HIV vaccine experts to support professional growth and career development in HIV vaccine science.
• Advocacy Initiatives Programmes that train advocates to champion HIV vaccine science, engage policy makers, and keep communities informed about the latest HIV vaccine research developments.

Quantifiable outcome

• 97 change makers supported through HIV Vaccine Academies since 2023
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• UNAIDS: The UN-led global health partnership coordinating the HIV response. Comparable as a global HIV advocacy and policy entity with overlapping stakeholders (policy makers, advocates, researchers); a broader incumbent operating at policy-system level.
• amfAR (Foundation for AIDS Research): A leading global nonprofit funding HIV/AIDS research, advocacy, and education. Comparable as a disease-specific nonprofit funder of HIV research and training, though broader in scope (cure, treatment, prevention) than the vaccine-specific network.
• International AIDS Society (IAS): The parent organization and host programme. IAS is the world's largest independent association of HIV professionals and runs the conferences, digital platform, and broader portfolio in which the HIV Vaccine Research Network sits; directly comparable as the same institution but at a wider portfolio scope.
• Elizabeth Glaser Pediatric AIDS Foundation: A global health nonprofit focused on pediatric HIV/AIDS research, prevention, and treatment. Comparable as a disease-specific HIV nonprofit combining research, advocacy, and capacity building, with a different population focus.
• Coalition for Epidemic Preparedness Innovations (CEPI): A global partnership that finances and coordinates vaccine development against epidemic threats. Comparable in vaccine R&D convening and funder model, though much broader in scope and larger in scale; a potential partnership pathway for the network.
• GAVI (Global Alliance for Vaccines and Immunization): A global vaccine alliance funding immunization access in lower-income countries. Comparable as a vaccine-focused alliance combining funder backing, African-led implementation, and advocacy — though focused on access/delivery rather than research capacity.

Direct peers

• Treatment Action Group (TAG): An independent AIDS research and policy advocacy organization. Directly comparable in combining HIV research literacy, advocate training, and policy engagement — a focused peer in operating model though broader in disease scope.
• HVTN (HIV Vaccine Trials Network): A global collaborative network conducting HIV vaccine clinical trials, with a strong footprint in Africa and a focus on engaging African investigators. Comparable in network-based HIV vaccine research mission, although execution is trial-driven rather than training-driven.
• International AIDS Vaccine Initiative (IAVI): A global nonprofit that develops and advocates for HIV vaccine research and access. Directly comparable in mission and beneficiary communities (African researchers, advocates, policy makers), with a stronger emphasis on vaccine discovery and trial design rather than capacity building.
• AVAC (Global Advocacy for HIV Prevention): An advocacy nonprofit focused on HIV prevention research, including vaccines, PrEP, and long-acting agents. Closely aligned in combining research literacy, advocacy training, and policy engagement for HIV prevention — a direct peer in mission and operating model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global HIV Vaccine Enterprise